A
85.21
0.83 (0.98%)
| Previous Close | 84.38 |
| Open | 83.82 |
| Volume | 542,787 |
| Avg. Volume (3M) | 513,212 |
| Market Cap | 4,725,654,016 |
| Price / Sales | 79.19 |
| Price / Book | 11.63 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -211.46% |
| Operating Margin (TTM) | -847.56% |
| Diluted EPS (TTM) | -2.99 |
| Quarterly Revenue Growth (YOY) | -79.30% |
| Total Debt/Equity (MRQ) | 12.76% |
| Current Ratio (MRQ) | 4.93 |
| Operating Cash Flow (TTM) | -114.70 M |
| Levered Free Cash Flow (TTM) | -10.43 M |
| Return on Assets (TTM) | -16.69% |
| Return on Equity (TTM) | -35.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Arcellx, Inc. | Bearish | Bearish |
AIStockmoo Score
1.8
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.75 |
|
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 14.50% |
| % Held by Institutions | 102.08% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 133.00 (Scotiabank, 56.09%) | Buy |
| Median | 129.00 (51.39%) | |
| Low | 88.00 (Cantor Fitzgerald, 3.27%) | Hold |
| Average | 116.67 (36.92%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 82.88 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 16 Oct 2025 | 129.00 (51.39%) | Buy | 88.85 |
| Cantor Fitzgerald | 09 Oct 2025 | 88.00 (3.27%) | Hold | 88.39 |
| Scotiabank | 31 Jul 2025 | 133.00 (56.08%) | Buy | 71.39 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Sep 2025 | Announcement | Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference |
| 07 Aug 2025 | Announcement | Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |